Markets
LLY

Lilly Announces Interim Analysis From EMPRISE Real-world Study

(RTTNews) - Eli Lilly and Co. (LLY) said that a new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty or EMPRISE real-world study on effectiveness shows that Jardiance or empagliflozin was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists.

The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease.

In this new interim analysis, Jardiance was associated with a reduction in risk of hospitalization for heart failure of 41% compared with DPP-4 inhibitors and of 17% compared with GLP-1 receptor agonists.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY

Latest Markets Videos